Search

Displaying results 6131 - 6140 of 10000 in total
  1. Drug

    MPI-674

    go.drugbank.com/drugs/DB05749
    Experimental

    MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. … AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.

  2. Drug

    Elsamitrucin

    go.drugbank.com/drugs/DB05129
    Investigational

    The cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human origin. (PMID: 8150873)

  3. Drug

    Zeteletinib

    go.drugbank.com/drugs/DB21491
    Investigational

    Zeteletinib has a monoisotopic molecular weight of 500.17 Da. … Zeteletinib is under investigation in clinical trial NCT03780517 (Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors).

    Synonyms: Ret inhibitor ds-5010
  4. Drug

    Xeruborbactam

    go.drugbank.com/drugs/DB21512
    Investigational

    Xeruborbactam has a monoisotopic molecular weight of 222.05 Da. … Xeruborbactam is under investigation in clinical trial NCT07104162 (A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment).

  5. Drug

    Gridegalutamide

    go.drugbank.com/drugs/DB21593
    Investigational

    Gridegalutamide has a monoisotopic molecular weight of 818.32 Da. … Gridegalutamide is under investigation in clinical trial NCT04428788 (Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer).

  6. Drug

    Docirbrutinib

    go.drugbank.com/drugs/DB21606
    Investigational

    Docirbrutinib has a monoisotopic molecular weight of 578.24 Da. … Docirbrutinib is under investigation in clinical trial NCT05602363 (AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma).

  7. Drug

    Lomedeucitinib

    go.drugbank.com/drugs/DB21649
    Investigational

    Lomedeucitinib has a monoisotopic molecular weight of 419.15 Da. … Lomedeucitinib is under investigation in clinical trial NCT05730725 (A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis).

  8. Drug

    Bimokalner

    go.drugbank.com/drugs/DB21717
    Investigational

    Bimokalner has a monoisotopic molecular weight of 355.1 Da. … Bimokalner is under investigation in clinical trial NCT06521190 (ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving Cisplatin).

  9. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

  10. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance